BillionToOne, Inc. Overview
Pro stress-test →BillionToOne is a precision molecular diagnostics company that leverages proprietary DNA counting technology to create ultra-sensitive tests for disease detection. The company serves two primary markets: prenatal screening with UNITY Complete and oncology liquid biopsies with Northstar Select/Response, positioning it at the intersection of high-growth precision medicine segments.
Strategic Profile
Pro stress-test →BillionToOne's competitive advantage stems from its Quantitative Counting Templates (QCT) platform, enabling single-molecule DNA detection for superior sensitivity and specificity. With strong 40-45% projected revenue growth (2025-2026), positive path to operating profitability, and expanding clinical adoption including international partnerships, the company is executing a scalable strategy to become a category-defining player in molecular diagnostics.
Competitive Landscape
Pro stress-test →BillionToOne competes in prenatal screening against Natera and Guardant Health's GRAIL, and in liquid biopsy against Guardant Health and Foundation Medicine. Its key differentiator is ultra-high sensitivity enabled by QCT technology, with published data showing superior performance. The company is carving out leadership in fetal antigen assessment and expanding oncology presence through partnerships and geographic expansion.
Industry Context
BillionToOne, Inc. operates in Precision Diagnostics & Molecular Testing.
Key facts
Founded: 2016 · Headquarters: Menlo Park, California · Employees: 620 · Revenue: $296M (2025E) · Market cap: $4.3B